Signant Health Acquires VirTrial
Signant Health has announced the acquisition of VirTrial, a provider of software solutions for remote site startup and decentralized clinical trial conduct.
In addition to VirTrial's tele-research platform, which includes secure video, audio, chat, and connected medical device capabilities for decentralized patient-site interaction and assessments, the agreement provides Signant with a solution to address remote site startup and monitoring. Known as Virtual Site Monitoring, the solution leverages wearable technology for in-house or outsourced clinical research associates to remotely conduct site evaluation, initiation, and monitoring visits.
For more information, click here.
Unifying Industry to Better Understand GCP Guidance
May 7th 2025In this episode of the Applied Clinical Trials Podcast, David Nickerson, head of clinical quality management at EMD Serono; and Arlene Lee, director of product management, data quality & risk management solutions at Medidata, discuss the newest ICH E6(R3) GCP guidelines as well as how TransCelerate and ACRO have partnered to help stakeholders better acclimate to these guidelines.
Phase III PROMINENT Trial Initiated to Evaluate Felzartamab for Primary Membranous Nephropathy
June 30th 2025The global Phase III PROMINENT trial has begun dosing patients to evaluate felzartamab in treating primary membranous nephropathy, a serious autoimmune kidney disorder with no FDA-approved therapies.
Funding Cuts Threaten Diversity in Clinical Research
June 27th 2025In this video interview, Kyle McAllister, co-founder, CEO, Trially, discusses how recent federal funding cuts are likely to undermine research focused on underrepresented populations, and why long-term investment in community-based studies is essential to closing persistent health equity gaps.
